Check out the latest features and columns!

Pharmaceutical Executive September 2022

September's Executive Profile features Kevin Ali, CEO of Organon

Building a New Legacy

Senior leaders in pharma, healthcare marketing and communications, and advertising got together to discuss the progress and lingering roadblocks in advancing diversity, equity, and inclusion strategies in the life sciences

DE&I in Pharma Sales & Marketing: ‘While There’s Work, There’s Promise’

Pharm Exec profiles its 2022 Emerging Pharma Leaders

Pharm Exec's 2022 Emerging Pharma Leaders

 The windfall from COVID-19 vaccines and treatments has shaken up Pharm Exec’s latest listing of the top global biopharma sales producers in record-breaking fashion

2022 Pharm Exec 50

Jill Wechsler is Pharm Exec's Washington Corespondent

Articles

The ‘skinny’ user fee reauthorization tables multiple high-profile proposals.

FDA Keeps Its User Fees, but Fails to Gain Important Reforms

The highly-regulated pharmaceutical industry poses serious challenges that can derail digital health programs. But, there are solutions.

Scale Down Before Scaling Up: Digital Innovation in a Highly Regulated Industry

Leo Tarkovsky brings more than 25 years of proven experience scaling companies in the healthcare space.

Fingerpaint Group Adds Chief Commercial Officer to Fuel Sustainable Growth

Hiring new employees may not be the answer to the war for talent.

Building the Pharma Talent of Tomorrow from Today’s Workforce

Under its Commercial License Agreement with OBT, Genmab will obtain the exclusive right to develop and commercialize novel antibody therapeutics utilizing OBT's novel, first-in-class IO antibody.

Oxford BioTherapeutics enters into Commercial License Agreement with Genmab

Fast-growing specialty pharma selects Veeva CRM and Veeva Vault PromoMats to build a unified foundation for commercial excellence.

Tillotts Standardizes on Veeva Commercial Cloud Applications to Power Digital Engagement in Europe 

Partner at Simon-Kucher & Partners, leading its life sciences division in greater China

The 2022 National Reimbursement Drug List will see more pressures for new inclusions on the one hand, and more certainties for renewals on the other. At the same time, the process is becoming more interactive and transparent.

China’s 2022 NRDL Outlook

Restructural changes effective immediately.

Promotions and Additions for Pharmaceutical Executive and Pharmaceutical Commerce Editorial Teams

Should pharma brands still maintain dedicated websites to engage HCPs?  Are they effective and trustworthy sources of information that offer intuitive and helpful experiences for the user? 

The Death Knell of Pharma HCP Websites

Agency releases a series of new guidances to advance the reliability of patient-focused tools and methods.

Featured Content

Pharmaceutical Executive September 2022

Building a New Legacy

DE&I in Pharma Sales & Marketing: ‘While There’s Work, There’s Promise’

Pharm Exec's 2022 Emerging Pharma Leaders

2022 Pharm Exec 50